Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 11 of 11 for “"CDK4/6 Inhibitor"”.
-
Impact of Cyclin-Dependent Kinase 4 and 6 Inhibitors on Chemotherapy Utilization and Overall Survival in Women with HR+/HER2– Metastatic Breast Cancer in the United States
… the impact of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor therapy class, introduced in 2015, on early chemotherapy utilization in an older population of patients with HR+/HER2– MBC in the United States (US). Methods: Using an interrupted time series design, patients with a confirmed …
-
Prevalence of Pik3ca-Mutations and Response to First-Line Endocrine Therapy in a Population of Bulgarian Patients with HR(+) HER2(–) Metastatic Breast Cancer // Честотата на PIK3CA-мутацията и отговорът към първа линия ендокринна терапия в популацията от български пациентки с HR(+)HER2(-) метастазирал карцином на гърдата
… survival and OS in first-line therapy with ET±CDK4/6 inhibitor in patients with confirmed PIK3CA mutation and those without mutation.
-
Mapping the cell cycle-dependent centrosomal interactome
… cell cycle synchronisation method based on the CDK4/6 inhibitor palbociclib. Differential analysis of the centrosome interactome resulted in the identification of proteins associated with numerous biological processes, including gene expression, DNA/RNA processing, and cell cycle regulation. …
-
Targeting Transcription Factors in Neuroblastoma: Development of Aurora Kinase A/N-Myc Degraders and ID2 Chemical Probes
… developed through chemical modifications of the CDK4/6 inhibitor ribociclib. A series of Aurora-A/N-Myc degraders were subsequently developed using proteolysis targeting chimera (PROTAC) technology. The representative compound, 2.3 (HLB-0532259), potently decreases N-Myc protein levels following …
-
Mathematical Modeling of Therapies for MCF7 Breast Cancer Cells
… which mimics the effects of an aromatase inhibitor, or fulvestrant, an ER degrader. These data were used to calibrate a mathematical model based on key interactions between ER signaling and the cell cycle. We show that the calibrated model is capable of predicting the combination treatment …
-
Mechanisms of medulloblastoma vulnerability and new targeted therapies
… and more effective alternative to palbociclib, a CDK4/6 inhibitor currently pursued in clinical studies. We present evidence supporting dinaciclib’s ability to inhibit MB proliferation, impair cancer stemness and induce apoptosis at considerably lower doses than palbociclib. Furthermore, …
-
Characterization of novel small molecule inhibitors of FOXM1 as potential therapeutic agents for breast cancer
… cancers. Despite this compelling evidence, no inhibitors of FOXM1 that have therapeutic potential have emerged due to lack of specificity and potency, and importantly, poor pharmacokinetic profiles in animals. To this end, we have identified and characterized novel inhibitors of FOXM1 that …
-
Does inappropriate DNA replication provide a mechanism for the de novo acquisition of drug resistance?
… was further heightened when combined with PARP inhibitors. Notably, combining Osimertinib with either Palbociclib (a CDK4/6 inhibitor) or AZD1390 (an ATM inhibitor) enhanced cell killing beyond single-agent Osimertinib, with only the Palbociclib combination reducing the replicative fraction of …
-
Dissecting the molecular mechanisms of therapeutic resistance in cancer
… cell-lines. SFK inhibition also prevented EGFR inhibitor-induced EMT and drug resistance in NSCLC cells both in vitro and in vivo. Mechanistically, SFK activation stabilized ZEBI by promoting ERK1/2-mediated phosphorylation on three serine residues, S583, S646, and S679. Consequently, MEK …
-
Targeting Autophagy to Improve Efficacy of Cdk4/6 Inhibition In Breast Cancer
… and tumorigenesis. The crucial role of the CDK4/6-Cyclin D pathway has led to the development and FDA approval (palbociclib, ribociclib) of CDK4/6 inhibitors for the treatment of advanced estrogen receptor positive breast cancer. However, three major clinical challenges remain: i) adverse …
-
Overcoming Resistance to CDK4/6-targeted Therapy Using JAK2/STAT3 Inhibitor in Triple-Negative Breast Cancer
… and metastasis. Cyclin-dependent kinase 4 and 6 (CDK4/6) are major cell cycle regulators that control G1 to S phase transition and aberrant hyperactivation of the CDK4/6 pathway results in uncontrolled cell proliferation. Although three CDK4/6 inhibitors (CDK4/6is) have achieved clinical benefits …